Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...
SACRAMENTO, Calif., May 19, 2025 /PRNewswire/ -- Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results